Glimepiride is a third-generation sulfonylurea oral hypoglycemic agent used in the management of Type 2 Diabetes Mellitus. It is an insulin secretagogue that stimulates the release of insulin from functional pancreatic beta cells. The 1mg strength is a common starting and maintenance dose in the Indian population, offering a favorable balance between glycemic efficacy and risk of hypoglycemia.
Adult: Initial dose: 1 mg once daily, taken with breakfast or the first main meal. Maintenance dose: 1-4 mg once daily. Dose can be increased in increments of 1-2 mg at 1-2 week intervals based on glycemic response. The maximum recommended dose is 8 mg/day, but doses above 4 mg provide little additional benefit in most Indian patients.
Note: Take once daily, preferably with breakfast or the first main meal of the day. Do not skip meals after taking the dose. Tablets should be swallowed whole with a glass of water.
Glimepiride binds to the sulfonylurea receptor (SUR1) on the ATP-sensitive potassium (K-ATP) channels of pancreatic beta cells. This binding leads to closure of the K-ATP channels, depolarization of the beta cell membrane, opening of voltage-gated calcium channels, influx of calcium, and subsequent exocytosis of insulin-containing secretory granules.
Pregnancy: Pregnancy Category C (US FDA). Not recommended during pregnancy. Insulin is the drug of choice for glycemic control in pregnant diabetic women. Glimepiride may cross the placenta and cause neonatal hypoglycemia.
Driving: Caution advised. Hypoglycemia can impair concentration and reaction time. Patients should be aware of the symptoms of hypoglycemia, especially when driving or operating machinery.
| Other Antidiabetics (Insulin, Metformin) | Additive hypoglycemic effect, increased risk of hypoglycemia. | Major |
| Beta-blockers (e.g., Propranolol) | May mask tachycardia as a warning sign of hypoglycemia; may potentiate hypoglycemic effect. | Moderate |
| Fluconazole, Miconazole | Inhibit CYP2C9, increasing glimepiride plasma levels and risk of hypoglycemia. | Major |
| Rifampicin | Induces CYP2C9, decreasing glimepiride plasma levels and reducing efficacy. | Moderate |
| Warfarin | Glimepiride may potentiate the anticoagulant effect of warfarin. | Moderate |
| NSAIDs (e.g., Ibuprofen) | May potentiate hypoglycemic effect; increased risk of hypoglycemia. | Moderate |
| Sulfonamides (Co-trimoxazole) | May displace glimepiride from protein binding sites, increasing hypoglycemic effect. | Moderate |
| ACE Inhibitors (e.g., Enalapril) | May enhance hypoglycemic effect. | Moderate |
| Thiazide Diuretics (e.g., Hydrochlorothiazide) | May cause hyperglycemia, reducing glimepiride efficacy. | Moderate |
| Corticosteroids (e.g., Prednisolone) | May cause hyperglycemia, reducing glimepiride efficacy. | Moderate |